Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

DV201P-RNA

Phase 1Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

DV201P-RNA is one of 37 biologic programs targeting HIV. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

36

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIVRecruiting

HIVPhase 1

Recruiting

Competition

Competitive Landscape

57 competitors in HIV

#DrugCompanyPhaseTrials

Cabenuva

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Tivicay

Epivir

GGlaxo Dba Glaxosmithkline

Sunlenca

Biktarvy

Emtriva

Vemlidy

Lamprene

Priftin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

HIV

NCT07390474

Clinical

Trials by Indication[1]

HIV1 trial

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07390474·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DV201P-RNA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DV201P-RNA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DV201P-RNA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Related News